271
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Burden of Sickle Cell Disease on Children and Their Caregivers: Caregiver Reports of Children’s Health-Related Quality of Life and School Experiences, Caregiver Burden, and Their Association with Frequency of Vaso-Occlusive Crises

, ORCID Icon, , , , & ORCID Icon show all
Pages 369-381 | Received 03 May 2023, Accepted 28 Oct 2023, Published online: 27 Nov 2023
 

Abstract

Background

Children with sickle cell disease (SCD) experience a multiplex of disease-related symptoms and complications, including vaso-occlusive crises (VOCs), episodes characterized by extreme pain.

Methods

A cross-sectional observational survey examined the health-related quality of life (HRQoL) and school experiences of children with SCD 2 months–11 years, burden experienced by their caregivers, and associations between these outcomes and VOC frequency. Caregivers (N=167) of children with SCD in the US completed the Infant-Toddler Quality of Life-Short Form 47 (ITQoL-SF47) for children 2 months–4 years, the Child Health Questionnaire–Parent Form 50 (CHQ-PF50) and PROMIS Pain Interference and Sleep Disturbance Parent Proxy short forms for children 5–11 years, and a study-specific survey of school experiences.

Results

Children with SCD 2 months–4 years had lower ITQoL-SF47 scores (ie, worse HRQoL, p<0.001) than a normative sample of children; across domains, differences ranged from 18.73–45.03 points and exceeded minimal important difference (MID) thresholds. Except for the behavior domain, children with SCD 5–11 years had lower scores on all CHQ-PF50 domains than the normative sample (p<0.001); differences ranged from 6.78–36.37 points and exceeded MID thresholds. Children with more frequent VOCs had lower HRQoL and worse school experiences than children with less frequent VOCs (p<0.05, except for behavior domains). The largest differences based on VOC frequency were observed for overall health and bodily pain/discomfort among children 2 months–4 years (differences=40.88 and 32.50 points, respectively), and bodily pain and role/social limitations due to physical health among children 5–11 years (differences=38.99 and 37.80, respectively). Caregivers of children with more frequent VOCs experienced greater burden than caregivers of children with less frequent VOCs, though specific areas of impact (eg, caregiver emotions, time) differed across child age groups.

Conclusion

VOC frequency is negatively associated with HRQoL, highlighting the burden experienced by children with SCD and their caregivers.

Abbreviations

CHQ-PF50, Child Health Questionnaire – Parent Form 50; HRQoL, Health-related quality of life; ITQoL-SF47, Infant-Toddler Quality of Life-Short Form 47; MID, Minimal important difference; SCD, Sickle cell disease; SD, Standard deviation; VOC, Vaso-occlusive crisis.

Ethics and Informed Consent

All procedures involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The informed consent form, protocol, and recruitment materials were approved by the Western Copernicus Group Independent Review Board (WCG IRB # 20203536). WCG is an independent review board, as opposed to a board that is affiliated with a specific hospital, university, or other institution. As this was not site-based research, approval from individual institutions’ boards was not necessary. All participants consented to participating in the study.

Acknowledgments

We would like to thank the caregivers who participated in this study; their time, interest, and insight is greatly appreciated.

Disclosure

GPY, JP, SL, and SI are employees of Novartis Pharmaceuticals Corporation. GPY and JP also own stock in the company. AC has received consultancy and research funding from Novartis Pharmaceuticals Corporation. He also reports grants for clinical trial and/or consultancy from Global Blood Therapeutics, Agios, Vertex, and Bluebird Bio, outside the submitted work. AAR and KLM are employees of QualityMetric Incorporated, LLC, and received funding from Novartis Pharmaceuticals Corporation to conduct this research. After the study was conducted, QualityMetric acquired ownership of the HealthActCHQ family of surveys, which includes the CHQ-PF50 and the ITQoL-SF47. The authors report no other conflicts of interest in this work.